Celltrion highlights biosimilar savings on 10th anniversary in Europe

South Korea’s Celltrion Healthcare (Kosdaq: 068270) has launched
a campaign to celebrate a decade of continuous biosimilar
innovation in Europe.

The campaign coincides with 10 years since the world’s first
monoclonal antibody biosimilar infliximab, Remsima, received
regulatory approval from the European Medicines Agency, as a copy
of Janssen’s biologic Remicade.

Celltrion has stressed how, during the decade since, thousands of
patients in…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.